TD Asset Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-157,892
| Closed | -$27.2M | – | 1581 |
|
|
2021
Q3 | $27.2M | Buy |
157,892
+15,151
| +11% | +$1.98M | 0.03% | 403 |
|
|
2021
Q2 | $17.9M | Buy |
142,741
+3,711
| +3% | +$468K | 0.02% | 504 |
|
|
2021
Q1 | $18.9M | Buy |
139,030
+13,528
| +11% | +$1.75M | 0.02% | 481 |
|
|
2020
Q4 | $16.1M | Buy |
125,502
+9,274
| +8% | +$1.09M | 0.02% | 481 |
|
|
2020
Q3 | $13.1M | Buy |
116,228
+13,460
| +13% | +$1.34M | 0.02% | 485 |
|
|
2020
Q2 | $9.79M | Buy |
102,768
+12,807
| +14% | +$1.23M | 0.01% | 516 |
|
|
2020
Q1 | $8.09M | Buy |
89,961
+10,053
| +13% | +$781K | 0.01% | 526 |
|
|
2019
Q4 | $4.24M | Sell |
79,908
-2,700
| -3% | -$123K | 0.01% | 751 |
|
|
2019
Q3 | $3.26M | Sell |
82,608
-1,200
| -1% | -$52.1K | 0.01% | 788 |
|
|
2019
Q2 | $3.44M | Sell |
83,808
-18,794
| -18% | -$778K | 0.01% | 780 |
|
|
2019
Q1 | $4.78M | Sell |
102,602
-16,319
| -14% | -$717K | 0.01% | 704 |
|
|
2018
Q4 | $5.18M | Buy |
118,921
+10,900
| +10% | +$545K | 0.01% | 650 |
|
|
2018
Q3 | $6.18M | Buy |
108,021
+19,321
| +22% | +$949K | 0.01% | 666 |
|
|
2018
Q2 | $4.3M | Buy |
88,700
+16,000
| +22% | +$583K | 0.01% | 756 |
|
|
2018
Q1 | $2.84M | Buy |
72,700
+11,200
| +18% | +$476K | ﹤0.01% | 812 |
|
|
2017
Q4 | $2.61M | Hold |
61,500
| – | – | ﹤0.01% | 828 |
|
|
2017
Q3 | $2.29M | Sell |
61,500
-17,300
| -22% | -$601K | ﹤0.01% | 837 |
|
|
2017
Q2 | $2.4M | Buy |
78,800
+600
| +0.8% | +$17.4K | ﹤0.01% | 834 |
|
|
2017
Q1 | $2.07M | Buy |
78,200
+5,200
| +7% | +$137K | ﹤0.01% | 880 |
|
|
2016
Q4 | $1.86M | Buy |
73,000
+8,000
| +12% | +$253K | ﹤0.01% | 877 |
|
|
2016
Q3 | $2.35M | Buy |
65,000
+3,000
| +5% | +$99.4K | ﹤0.01% | 847 |
|
|
2016
Q2 | $2.11M | Buy |
62,000
+900
| +1% | +$29.3K | ﹤0.01% | 849 |
|
|
2016
Q1 | $1.61M | Sell |
61,100
-2,000
| -3% | -$58.2K | ﹤0.01% | 872 |
|
|
2015
Q4 | $3.08M | Buy |
63,100
+500
| +0.8% | +$18K | 0.01% | 767 |
|
|
2015
Q3 | $1.56M | Buy |
62,600
+700
| +1% | +$21K | ﹤0.01% | 852 |
|
|
2015
Q2 | $1.96M | Sell |
61,900
-1,500
| -2% | -$48.4K | ﹤0.01% | 859 |
|
|
2015
Q1 | $2.41M | Buy |
63,400
+6,500
| +11% | +$258K | ﹤0.01% | 809 |
|
|
2014
Q4 | $2.22M | Buy |
56,900
+1,500
| +3% | +$52.3K | ﹤0.01% | 826 |
|
|
2014
Q3 | $1.68M | Sell |
55,400
-400
| -0.7% | -$11.3K | ﹤0.01% | 848 |
|
|
2014
Q2 | $1.9M | Buy |
55,800
+24,600
| +79% | +$823K | ﹤0.01% | 833 |
|
|
2014
Q1 | $1.08M | Buy |
31,200
+20,100
| +181% | +$907K | ﹤0.01% | 899 |
|
|
2013
Q4 | $440K | Buy |
+11,100
| New | +$268K | ﹤0.01% | 1053 |
|
TD Asset Management's XLRN Position: Q4 2021 in Review
TD Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 157,892 shares — an estimated $27.2M sold.
TD Asset Management first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $27.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- TD Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- TD Asset Management sold 157,892 Acceleron Pharma shares in Q4 2021, an estimated $27.2M.
- TD Asset Management first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- TD Asset Management's Acceleron Pharma position peaked at $27.2M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on TD Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.